2021
Factors associated with late risks of breast cancer-specific mortality in the SEER registry
Leone JP, Vallejo CT, Hassett MJ, Leone J, Graham N, Tayob N, Freedman RA, Tolaney SM, Leone BA, Winer EP, Lin NU. Factors associated with late risks of breast cancer-specific mortality in the SEER registry. Breast Cancer Research And Treatment 2021, 189: 203-212. PMID: 33893907, PMCID: PMC8302525, DOI: 10.1007/s10549-021-06233-4.Peer-Reviewed Original ResearchConceptsBC-specific mortalityHR-positive breast cancerHR-negative breast cancerBreast cancerHR statusCumulative riskBreast cancer-specific mortalityCancer-specific mortalityT1a/bHormone receptor statusYear of diagnosisKaplan-Meier analysisLong-term riskBC deathConclusionThe risksGray regressionN2 diseaseLate relapseReceptor statusLate recurrenceSEER registryLater riskClinical trialsYear 5PatientsExamination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study
Pathipati MP, Yohannan TK, Tian L, Hornbacker K, Benson JA, Berry GJ, Lui NS, Kunz PL, Padda SK. Examination of factors associated with lymph node metastases in lung carcinoids: Results from a single institution retrospective cohort study. Lung Cancer 2021, 154: 186-194. PMID: 33551175, PMCID: PMC8026717, DOI: 10.1016/j.lungcan.2021.01.017.Peer-Reviewed Original ResearchConceptsLung neuroendocrine tumorsLymph nodesNeuroendocrine tumorsLung carcinoidsSSTR imagingLN metastasisAtypical carcinoidExact testSingle-institution retrospective cohort studyLymph node-positive diseaseAssociation of lymphPositive lymph nodesRetrospective cohort studyLymph node diseaseLymph node involvementNode-positive diseaseLymph node metastasisMultivariable logistic regressionFisher's exact testPre-operative workupN2 diseaseAdjuvant therapyLN involvementN1 diseaseNode involvement
2019
A new approach to predicting risk for N2 disease in non-small cell lung cancer
Decker RH, Blasberg JD. A new approach to predicting risk for N2 disease in non-small cell lung cancer. Journal Of Thoracic Disease 2019, 1: s1973-s1975. PMID: 31632801, PMCID: PMC6783735, DOI: 10.21037/jtd.2019.07.61.Peer-Reviewed Original Research
2018
Chapter 8 Special Types of Lung Cancer
Blasberg J, Kim C, Chilakamarry S. Chapter 8 Special Types of Lung Cancer. 2018, 131-146. DOI: 10.1016/b978-0-323-48565-4.00008-4.Peer-Reviewed Original ResearchNon-small cell lung cancerLung cancerPancoast tumorPatient fitnessMultifocal non-small cell lung cancerSolid non-small cell lung cancerFeasibility of resectionLung cancer subsetsExtent of diseaseCell lung cancerMultidisciplinary tumor boardEvidence-based recommendationsSpectrum of diseaseMultifocal lung cancerUnique considerationsGround-glass nodulesN2 diseaseSynchronous diseaseThoughtful workupTrimodality therapyDistant diseaseSurgical resectionYounger patientsPreoperative workupCarcinoid tumors
2017
The Significance of Upfront Knowledge of N2 Disease in Non‐small Cell Lung Cancer
Thomas DC, Arnold BN, Rosen JE, Salazar MC, Detterbeck FC, Blasberg JD, Boffa DJ, Kim AW. The Significance of Upfront Knowledge of N2 Disease in Non‐small Cell Lung Cancer. World Journal Of Surgery 2017, 42: 161-171. PMID: 28799084, DOI: 10.1007/s00268-017-4165-6.Peer-Reviewed Original ResearchConceptsNon-small cell lung cancerUnsuspected N2 diseaseIII-N2 non-small cell lung cancerN2 diseaseCell lung cancerSurgical resectionAdjuvant chemotherapyAdjuvant therapyOverall survivalPathologic stageLung cancerMultivariate analysisCurative-intent surgical resectionStage IIIA NSCLCHigher comorbidity scoreNational Cancer DatabaseIndependent risk factorKaplan-Meier analysisCN2 diseaseIIIA NSCLCComorbidity scoreCancer DatabaseRisk factorsRetrospective analysisRadiation therapyLUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts).
Burtness B, Haddad R, Dinis J, Trigo Perez J, Yokota T, Viana L, Romanov I, Vermorken J, Bourhis J, Tahara M, Segalla J, Psyrri A, Vasilevskaya I, Nangia C, Chaves-Conde M, Wang B, Gibson N, Ehrnrooth E, Harrington K, Cohen E. LUX-head and neck 2: Randomized, double-blind, placebo-controlled, phase III trial of afatinib as adjuvant therapy after chemoradiation (CRT) in primary unresected, high/intermediate-risk, squamous cell cancer of the head and neck (HNSCC) patients (pts). Journal Of Clinical Oncology 2017, 35: 6001-6001. DOI: 10.1200/jco.2017.35.15_suppl.6001.Peer-Reviewed Original ResearchDisease-free survivalPhase III trialsIII trialsEGFR inhibitionMedian disease-free survivalRecurrent/metastatic diseaseErbB family blocker afatinibPre-planned interim analysisECOG PS 0Median treatment durationSquamous cell cancerDefinitive chemoradiationECOG PSEligible ptsAdvanced HNSCCConcurrent cisplatinN2 diseasePrimary endpointAdjuvant therapyMetastatic diseasePS 0Complete responseDisease recurrenceMedian ageNodal stageIndications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT
Gao SJ, Kim AW, Puchalski JT, Bramley K, Detterbeck FC, Boffa DJ, Decker RH. Indications for invasive mediastinal staging in patients with early non-small cell lung cancer staged with PET-CT. Lung Cancer 2017, 109: 36-41. PMID: 28577947, DOI: 10.1016/j.lungcan.2017.04.018.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overCarcinoma, Non-Small-Cell LungClinical Decision-MakingDiagnostic ImagingFemaleHumansLung NeoplasmsMaleMediastinumMiddle AgedNeoplasm MetastasisNeoplasm StagingPatient SelectionPositron Emission Tomography Computed TomographyPractice Guidelines as TopicRetrospective StudiesConceptsOccult N2 diseaseOccult N2 metastasesGround-glass componentInvasive mediastinal stagingCurative-intent therapyT2 tumorsN2 metastasisPET-CTInvasive stagingN2 diseaseT1 tumorsNegative predictive valueMediastinal stagingEarly non-small cell lung cancerExact testPredictive valueSolid tumorsNon-small cell lung cancerClinical stage I NSCLCN2 lymph nodesNode-negative NSCLCOccult nodal involvementPure-solid tumorsStage I NSCLCT1-2N0 disease
2014
Lung cancer staging: the value of PET depends on the clinical setting
Detterbeck FC, Figueroa Almanzar S. Lung cancer staging: the value of PET depends on the clinical setting. Journal Of Thoracic Disease 2014, 6: 1714-23. PMID: 25589964, PMCID: PMC4283348, DOI: 10.3978/j.issn.2072-1439.2014.11.16.Peer-Reviewed Original ResearchClinical settingEvaluation of patientsInvasive mediastinal stagingPositron emission tomography (PET) imagingEmission Tomography ImagingValue of PETInvasive stagingImpact of PETM1 diseaseN2 diseasePET findingsMediastinal stagingLung cancerRealist synthesis methodResectionClinical contextTomography imagingPatientsRCTsEvaluation of differencesHigher chanceStagingInconsistent resultsDiseaseTraditional imaging
2009
A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results?
Enestvedt C, Diggs B, Shipley D, Thomas C, Billingsley K. A population-based analysis of surgical and adjuvant therapy for resected gastric cancer: are patients receiving appropriate treatment following publication of the intergroup 0116 results? Gastrointestinal Cancer Research : GCR 2009, 3: 233-8. PMID: 21151426, PMCID: PMC3000069.Peer-Reviewed Original ResearchReceipt of chemoradiotherapyAdjuvant therapyAdjuvant chemoradiotherapyIndependent predictorsGastric adenocarcinomaGastric cancerResectable gastric adenocarcinomaModest survival benefitAmerican Joint CommitteeCurrent practice patternsState Cancer RegistryStandard of carePopulation-based analysisAnalysis of survivalGastric cancer treatmentChi-square testBinary logistic regressionEligible patientsN2 diseaseTreatment eraResection typeSurvival benefitLymph nodesAJCC stageCancer Registry
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply